Stock Scorecard
Stock Summary for Alnylam Pharmaceuticals Inc (ALNY) - $143.31 as of 4/26/2024 8:52:50 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ALNY
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ALNY
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ALNY
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ALNY
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for ALNY
Financial Details for ALNY
Company Overview |
|
---|---|
Ticker | ALNY |
Company Name | Alnylam Pharmaceuticals Inc |
Country | USA |
Description | Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 143.31 |
Last Day Price Updated | 4/26/2024 8:52:50 PM EST |
Last Day Volume | 479,135 |
Average Daily Volume | 535,987 |
52-Week High | 218.88 |
52-Week Low | 141.97 |
Last Price to 52 Week Low | 0.94% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 79.17 |
Sector PE | 56.64 |
5-Year Average PE | -24.40 |
Free Cash Flow Ratio | 7.43 |
Industry Free Cash Flow Ratio | 12.71 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 3.08 |
Total Cash Per Share | 19.29 |
Book Value Per Share Most Recent Quarter | -1.75 |
Price to Book Ratio | 142.92 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 10.27 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 126,452,000 |
Market Capitalization | 18,121,836,120 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 2.52% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 61.08% |
Reported EPS 12 Trailing Months | -3.52 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -3.56 |
Net Income Twelve Trailing Months | -440,242,000 |
Net Income Past Year | -440,242,000 |
Net Income Prior Year | -1,131,156,000 |
Quarterly Revenue Growth YOY | 31.20% |
5-Year Revenue Growth | 86.87% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 2,439,382,000 |
Total Cash Past Year | 2,439,382,000 |
Total Cash Prior Year | 2,192,406,000 |
Net Cash Position Most Recent Quarter | 1,418,606,000 |
Net Cash Position Past Year | 1,418,606,000 |
Long Term Debt Past Year | 1,020,776,000 |
Long Term Debt Prior Year | 1,016,942,000 |
Total Debt Most Recent Quarter | 1,020,776,000 |
Equity to Debt Ratio Past Year | -0.28 |
Equity to Debt Ratio Most Recent Quarter | -0.28 |
Total Stockholder Equity Past Year | -220,644,000 |
Total Stockholder Equity Prior Year | -158,223,000 |
Total Stockholder Equity Most Recent Quarter | -220,644,000 |
Options |
|
Put/Call Ratio | 6.46 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -2.22 |
MACD Signal | -1.79 |
20-Day Bollinger Lower Band | 128.31 |
20-Day Bollinger Middle Band | 164.98 |
20-Day Bollinger Upper Band | 201.66 |
Beta | 0.40 |
RSI | 37.45 |
50-Day SMA | 176.73 |
200-Day SMA | 171.74 |
System |
|
Modified | 4/26/2024 5:34:02 PM EST |